| operationId | operation_label | resultGroup1_groupingId | resultGroup1_grouping_label | resultGroup1_groupId | resultGroup1_group_label | resultGroup2_groupingId | resultGroup2_grouping_label | resultGroup2_groupId | resultGroup2_group_label | rawValue | formattedValue |
|---|
| Mth01_CatVar_Summ_ByGrp_1_n | n | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_1 | Placebo | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_1 | Male | 33 | 33 |
| Mth01_CatVar_Summ_ByGrp_1_n | n | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_1 | Placebo | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_2 | Female | 53 | 53 |
| Mth01_CatVar_Summ_ByGrp_1_n | n | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_2 | Xanomeline Low Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_1 | Male | 34 | 34 |
| Mth01_CatVar_Summ_ByGrp_1_n | n | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_2 | Xanomeline Low Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_2 | Female | 50 | 50 |
| Mth01_CatVar_Summ_ByGrp_1_n | n | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_3 | Xanomeline High Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_1 | Male | 44 | 44 |
| Mth01_CatVar_Summ_ByGrp_1_n | n | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_3 | Xanomeline High Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_2 | Female | 40 | 40 |
| Mth01_CatVar_Summ_ByGrp_2_pct | % | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_1 | Placebo | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_1 | Male | 38.3720930232558 | ( 38.4) |
| Mth01_CatVar_Summ_ByGrp_2_pct | % | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_1 | Placebo | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_2 | Female | 61.6279069767442 | ( 61.6) |
| Mth01_CatVar_Summ_ByGrp_2_pct | % | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_2 | Xanomeline Low Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_1 | Male | 40.4761904761905 | ( 40.5) |
| Mth01_CatVar_Summ_ByGrp_2_pct | % | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_2 | Xanomeline Low Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_2 | Female | 59.5238095238095 | ( 59.5) |
| Mth01_CatVar_Summ_ByGrp_2_pct | % | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_3 | Xanomeline High Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_1 | Male | 52.3809523809524 | ( 52.4) |
| Mth01_CatVar_Summ_ByGrp_2_pct | % | AnlsGrouping_01_Trt | Treatment | AnlsGrouping_01_Trt_3 | Xanomeline High Dose | AnlsGrouping_02_Sex | GenderSex | AnlsGrouping_02_Sex_2 | Female | 47.6190476190476 | ( 47.6) |